Glanzmann thrombasthenia At least 130 mutations in the ITGB3 gene have been found to cause Glanzmann thrombasthenia, which is a rare bleeding disorder. The mutations that cause this disorder occur in both copies of the gene in each cell and impair the production or activity of the beta3 subunit, which disrupts the formation of functional integrin αIIbβ3. A shortage (deficiency) of functional integrin αIIbβ3 prevents sufficient binding of fibrinogen or other proteins, impairing the formation of blood clots. A lack of platelet cohesion leads to prolonged or spontaneous bleeding episodes experienced by people with Glanzmann thrombasthenia. osteopetrosis Genetics Home Reference provides information about osteopetrosis. other disorders Mutations in the ITGB3 gene can also cause another rare bleeding disorder called platelet-type bleeding disorder 16. People with this disorder have signs and symptoms similar to Glanzmann thrombasthenia (described above), including frequent nosebleeds (epistaxis), bleeding from the gums, or red or purple spots on the skin caused by bleeding underneath the skin (petechiae), but the episodes are typically milder. Unlike Glanzmann thrombasthenia, this disorder results from a mutation in only one copy of the ITGB3 gene in each cell, and the mutations result in the formation of some integrin αIIbβ3 that is abnormally turned on (active), even when no clot is being formed. This abnormally active protein is unable to reach the surface of the platelet where it is needed to bind to other platelets during clot formation. The overactive integrin αIIbβ3 binds inappropriately to clotting proteins within the cell during the formation of platelets, causing the platelets to become misshapen and large. The abnormally shaped platelets have a shortened lifespan, so platelet numbers are often reduced, which impairs clot formation. (The combination of reduced numbers of enlarged platelets is referred to as macrothrombocytopenia.) Because the mutation that causes this disorder affects only one copy of the ITGB3 gene, some normal integrin is formed and normal platelets produced, which accounts for the mild signs and symptoms in affected individuals.

     The ITGB3 gene provides instructions for making the beta3 subunit of a receptor protein called integrin alphaIIb/beta3 (αIIbβ3), which is found on the surface of small cell fragments called platelets. Platelets circulate in blood and are an essential component of blood clots. The beta3 subunit attaches (binds) to the alphaIIb subunit, which is produced from the ITGA2B gene, to form integrin αIIbβ3. It is estimated that 80,000 to 100,000 copies of integrin αIIbβ3 are present on the surface of each platelet. During clot formation, integrin αIIbβ3 binds to a protein called fibrinogen. Attachment of integrin αIIbβ3 from adjacent platelets to the same fibrinogen protein helps platelets cluster together (platelet cohesion) to form a blood clot. Blood clots protect the body after injury by sealing off damaged blood vessels and preventing further blood loss. Integrin αIIbβ3 can also bind other proteins on platelets and in the blood as well as proteins within the intricate lattice that forms in the space between cells (extracellular matrix) to ensure proper clot formation and promote wound healing.

The following transcription factors affect gene expression:

• AhR
• NF-kappaB
• NF-kappaB1
• ER-alpha

Tissue specificity:

Isoform beta-3A and isoform beta-3C are widely expressed. Isoform beta-3A is specifically expressed in osteoblast cells; isoform beta-3C is specifically expressed in prostate and testis.

Molecular Function:

• Virus Receptor Activity
• Fibronectin Binding
• Protease Binding
• Protein Disulfide Isomerase Activity
• Platelet-Derived Growth Factor Receptor Binding
• Coreceptor Activity
• Enzyme Binding
• Identical Protein Binding
• Vascular Endothelial Growth Factor Receptor 2 Binding
• Cell Adhesion Molecule Binding
• Extracellular Matrix Binding

Biological Processes:

• Positive Regulation Of Protein Phosphorylation
• Positive Regulation Of Endothelial Cell Proliferation
• Platelet Degranulation
• Cell-Substrate Junction Assembly
• Cell Adhesion
• Cell-Matrix Adhesion
• Integrin-Mediated Signaling Pathway
• Blood Coagulation
• Positive Regulation Of Endothelial Cell Migration
• Negative Regulation Of Macrophage Derived Foam Cell Differentiation
• Negative Regulation Of Lipid Storage
• Smooth Muscle Cell Migration
• Cell Growth
• Platelet Activation
• Extracellular Matrix Organization
• Positive Regulation Of Vascular Endothelial Growth Factor Receptor Signaling Pathway
• Cell-Substrate Adhesion
• Activation Of Protein Kinase Activity
• Negative Regulation Of Lipid Transport
• Cell Adhesion Mediated By Integrin
• Heterotypic Cell-Cell Adhesion
• Substrate Adhesion-Dependent Cell Spreading
• Tube Development
• Apolipoprotein A-I-Mediated Signaling Pathway
• Wound Healing
• Regulation Of Bone Resorption
• Negative Regulation Of Low-Density Lipoprotein Particle Receptor Biosynthetic Process
• Viral Entry Into Host Cell
• Vascular Endothelial Growth Factor Receptor Signaling Pathway
• Mesodermal Cell Differentiation
• Positive Regulation Of Peptidyl-Tyrosine Phosphorylation
• Negative Regulation Of Lipoprotein Metabolic Process
• Leukocyte Migration
• Negative Chemotaxis
• Angiogenesis Involved In Wound Healing
• Platelet Aggregation

Drug Bank:

• Abciximab
• Anti-Thymocyte Globulin (Rabbit)
• Tirofiban
• Eptifibatide